Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey
Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2366532 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115230630150144 |
|---|---|
| author | Tina Bhutani Sayeli Jayade Sanika Rege Hannah Penton Vardhaman Patel Samaneh Kalirai Daniel Wolin Kimberly Boyle Lauren Seigel |
| author_facet | Tina Bhutani Sayeli Jayade Sanika Rege Hannah Penton Vardhaman Patel Samaneh Kalirai Daniel Wolin Kimberly Boyle Lauren Seigel |
| author_sort | Tina Bhutani |
| collection | DOAJ |
| description | Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over the past week or having ≥3% body surface area affected, despite treatment. Factors associated with residual disease and its effects on flare-ups, humanistic burden, and health care resource utilization (HCRU) were evaluated. Results: Of the 344 apremilast users (mean age, 44.9 years; female, 65.4%), 174 (50.6%) had residual disease. It was more prevalent in Black versus White participants (OR, 4.5; 95% CI, 1.6–12.2), those receiving apremilast for ≥1 versus <1 year (OR, 16.5; 95% CI, 7.9–34.4), those reporting ≥2 versus 0 to 1 flare-ups during the past 3 months (OR, 10.0; 95% CI, 5.0–20.1), and those with ≥4 versus 1 to 3 body regions affected at time of survey (OR, 8.6; 95% CI, 3.8–19.8). Participants with versus without residual disease self-reported more psoriasis flare-ups over the past 3 months (mean, 4.7 vs 0.9; p < .001) and more anxiety (89.7% vs 50.0%; p < .001) and depression (69.0% vs 23.6%; p < .001) over the past 30 days. Conclusion: Generally, participants with versus without residual disease also had significantly more comorbidities and greater HCRU. |
| format | Article |
| id | doaj-art-6a541e87403a42e39eeb760a48781c7a |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-6a541e87403a42e39eeb760a48781c7a2025-08-20T02:36:39ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2366532Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient surveyTina Bhutani0Sayeli Jayade1Sanika Rege2Hannah Penton3Vardhaman Patel4Samaneh Kalirai5Daniel Wolin6Kimberly Boyle7Lauren Seigel8Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA, USAOPEN Health Evidence & Access, Hingham, MA, USAOPEN Health Evidence & Access, Hingham, MA, USAOPEN Health Evidence & Access, Rotterdam, The NetherlandsResearch and Development, Bristol Myers Squibb, Princeton, NJ, USAResearch and Development, Bristol Myers Squibb, Princeton, NJ, USARTI Health Solutions, Research Triangle Park, NC, USARTI Health Solutions, Research Triangle Park, NC, USAResearch and Development, Bristol Myers Squibb, Princeton, NJ, USAPurpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over the past week or having ≥3% body surface area affected, despite treatment. Factors associated with residual disease and its effects on flare-ups, humanistic burden, and health care resource utilization (HCRU) were evaluated. Results: Of the 344 apremilast users (mean age, 44.9 years; female, 65.4%), 174 (50.6%) had residual disease. It was more prevalent in Black versus White participants (OR, 4.5; 95% CI, 1.6–12.2), those receiving apremilast for ≥1 versus <1 year (OR, 16.5; 95% CI, 7.9–34.4), those reporting ≥2 versus 0 to 1 flare-ups during the past 3 months (OR, 10.0; 95% CI, 5.0–20.1), and those with ≥4 versus 1 to 3 body regions affected at time of survey (OR, 8.6; 95% CI, 3.8–19.8). Participants with versus without residual disease self-reported more psoriasis flare-ups over the past 3 months (mean, 4.7 vs 0.9; p < .001) and more anxiety (89.7% vs 50.0%; p < .001) and depression (69.0% vs 23.6%; p < .001) over the past 30 days. Conclusion: Generally, participants with versus without residual disease also had significantly more comorbidities and greater HCRU.https://www.tandfonline.com/doi/10.1080/09546634.2024.2366532Cross-sectional surveyhumanistic burdenpsoriasis therapy |
| spellingShingle | Tina Bhutani Sayeli Jayade Sanika Rege Hannah Penton Vardhaman Patel Samaneh Kalirai Daniel Wolin Kimberly Boyle Lauren Seigel Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey Journal of Dermatological Treatment Cross-sectional survey humanistic burden psoriasis therapy |
| title | Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey |
| title_full | Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey |
| title_fullStr | Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey |
| title_full_unstemmed | Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey |
| title_short | Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey |
| title_sort | evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment results from a us patient survey |
| topic | Cross-sectional survey humanistic burden psoriasis therapy |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2366532 |
| work_keys_str_mv | AT tinabhutani evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey AT sayelijayade evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey AT sanikarege evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey AT hannahpenton evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey AT vardhamanpatel evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey AT samanehkalirai evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey AT danielwolin evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey AT kimberlyboyle evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey AT laurenseigel evaluatingprevalenceandconsequenceofresidualdiseaseinindividualswithpsoriasisreceivingapremilasttreatmentresultsfromauspatientsurvey |